MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02549651 |
Recruitment Status :
Completed
First Posted : September 15, 2015
Last Update Posted : February 27, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diffuse Large B-Cell Lymphoma | Drug: MEDI4736 Drug: tremelimumab Drug: AZD9150 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma. |
Actual Study Start Date : | July 13, 2016 |
Actual Primary Completion Date : | February 4, 2019 |
Actual Study Completion Date : | February 4, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: MEDI4736 |
Drug: MEDI4736
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion |
Experimental: MEDI4736 and tremelimumab |
Drug: MEDI4736
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion Drug: tremelimumab Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion |
Experimental: MEDI4736 and AZD9150 |
Drug: MEDI4736
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion Drug: AZD9150 AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion |
- Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events [ Time Frame: Screening through 90 days after the last dose of study medication ]
- Number of subjects experiencing dose-limiting toxicities [ Time Frame: First dose of study medications through 28 days after the administration of MEDI4736 or MEDI4736 and tremelimumab, 35 days after administration of MEDI4736 and AZD9150 ]Changes from baseline in laboratory parameters, vital signs, and ECGs
- Number of subjects who develop anti-drug antibodies (ADA) [ Time Frame: Screening through 90 days after last dose of study medication ]
- Time to Response [ Time Frame: Screening though 3 years after the last subject receives the first dose of study medication ]
- Duration of Response [ Time Frame: Screening though 3 years after the last subject receives the first dose of study medication ]
- Progression Free survival [ Time Frame: Screening though 3 years after the last subject receives the first dose of study medication ]
- Time to progression [ Time Frame: Screening though 3 years after the last subject receives the first dose of study medication ]
- Event free survival [ Time Frame: Screening though 3 years after the last subject receives the first dose of study medication ]
- Overall survival [ Time Frame: Screening though 3 years after the last subject receives the first dose of study medication ]
- MEDI4736 Maximum Plasma Concentration (Cmax) [ Time Frame: Measured at defined study visits from time of first dose through end of treatment ]
- Tremelimumab Maximum Plasma Concentration (Cmax) [ Time Frame: Measured at defined study visits from time of first dose through end of treatment ]
- AZD9150 Maximum Plasma Concentration (Cmax) [ Time Frame: Measured at defined study visits from time of first dose through end of treatment ]
- MEDI4736 Minimum Plasma Concentration (Cmin) [ Time Frame: Measured at defined study visits from time of first dose through end of treatment ]
- Tremelimumab Minimum Plasma Concentration (Cmin) [ Time Frame: Measured at defined study visits from time of first dose through end of treatment ]
- AZD9150 Minimum Plasma Concentration (Cmin) [ Time Frame: Measured at defined study visits from time of first dose through end of treatment ]
- Individual MEDI4736 Concentrations [ Time Frame: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months) ]
- Individual tremelimumab Concentrations [ Time Frame: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months) ]
- Individual AZD9150 Concentrations [ Time Frame: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months) ]
- Change from baseline of STAT3 RNA (signal transducer and activator of transcription) [ Time Frame: Measured at defined study visits from time of first dose through 90 days after last dose (approximately 15 months) ]
- Baseline PD-L1 protein expression within the tumor [ Time Frame: Measured on tumor samples provided at screening ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5 prior lines of therapy
- Eastern Cooperative Group (ECOG) performance status of 0 or 1
- Measurable disease by International Working Group (IWG) response criteria for lymphoma
- Adequate organ and marrow function
Exclusion Criteria:
- Previous immune-mediated therapy
- Subjects with prior ASCT or allogenic HCT. Subjects ineligible for available curative options after failing ASCT and have met the hematologic criteria are eligible to participate in this study. Subjects with prior allogenic HCT will be excluded.
- Documented current central nervous system involvement
3. Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02549651
United States, California | |
Research Site | |
La Jolla, California, United States, 92093 | |
United States, Maryland | |
Research Site | |
Baltimore, Maryland, United States, 21201 | |
United States, New Mexico | |
Research Site | |
Albuquerque, New Mexico, United States, 87131 | |
United States, North Carolina | |
Research Site | |
Durham, North Carolina, United States, 27710 | |
United States, South Carolina | |
Research Site | |
Charleston, South Carolina, United States, 29425 | |
United States, Texas | |
Research Site | |
Dallas, Texas, United States, 75390 | |
Research Site | |
Houston, Texas, United States, 77030 | |
United States, Wisconsin | |
Research Site | |
Milwaukee, Wisconsin, United States, 53226 | |
France | |
Research Site | |
Marseille, France, 13273 | |
Research Site | |
Villejuif, France, 94805 | |
Ireland | |
Research Site | |
Dublin 8, Ireland | |
Research Site | |
Galway, Ireland | |
United Kingdom | |
Research Site | |
Leicester, United Kingdom, LE1 5WW |
Study Director: | MedImmune LLC | MedImmune LLC |
Responsible Party: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT02549651 |
Other Study ID Numbers: |
D4190C00023 |
First Posted: | September 15, 2015 Key Record Dates |
Last Update Posted: | February 27, 2019 |
Last Verified: | February 2019 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
DLBCL MEDI4736 durvalumab tremelimumab AZD9150 |
anti-PD-L1 anti-CTLA-4 immunotherapy IMTC STAT3 |
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Durvalumab Tremelimumab Antineoplastic Agents, Immunological Antineoplastic Agents |